ATRC AtriCure, Inc.
Research report · from SEC EDGAR · close 2026-07-13
$34.80 +1.5%
$1.76B mkt cap
executive summary
AtriCure, Inc. (ATRC) is a $1.76B company. Revenue is $534.5M (+14.9% y/y) at a -2% net margin. It is not yet profitable. Our health score is B (81/100). No major red flags on file. It funds itself; low dilution risk.
Revenue (FY)
$534.5M
+14.9% y/y
✓ No major red flags from our filing-based checks.
who's buying
Insider buys / sells
0 / 3
Cash & ST investments
$146.2M
Operating cash flow
$57.3M
Dilution shelf
active shelf
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices — every figure is real and sourced; nothing is fabricated or predicted. Filings lag 40–90 days. Educational, not investment advice. Generated 2026-07-13 by stocktools.ai.